CAS No: 120511-73-1
Formulae hypotheticae: 120511-73-1
M. pondus: 293.37
Aspectus: Pulvis albus.
Assay: 99%
Qualis vexillum: USP 32
Anastrozole is the generic name for the trade name drug Arimidex. In quibusdam, health care professionals may use the trade name Arimidex when referring to the generic drug name Anastrozole. It is an aromatase inhibitor, an anti-cancer medication use for the adjuvant or initial treatment of breast cancer in post-menopausal women. Estrogen causes or increases growth of certain breast cancers. Anastrozole works by blocking aromatase enzyme, which is involved in estrogen production in the body. This leads to decreased tumor size or delayed progression of tumor growth in some women. The FDA approved brand name anastrozole (Arimidex) in 1995.
Anastrozole incipiet sumere eam diem quam suum cyclum incipiunt, Anastrozole eam per durationem moleculas administratio curret. Magni momenti est Anastrozole etiam demonstrare facultatem GP Anastrozolis augendi testosterone in corpore.. Studia quaedam demonstraverunt gradus testosterones naturales tantum habere incrementa 60% post usum huius substantiae 7 diebus. Propter hoc, fabricatores inveniunt Anastrozolem maxime efficacem in PCT ubi dum conantur gradus naturales quam maxime elevare ad vitandum post cyclum "fragore".
Anastrozole interdum solebat tractare cancer masculum pectus, sed in viris non bene tatum est. Alrimidex pro sterilibus hominibus studetur aequare testosterone gradus et semen sanum valere.. Aliqui masculi athletae et fabricatores anabolicas steroids ad musculum aedificandum capiunt etiam Arimidex ad productionem estrogen redigendum, quae parte effectus moleculas usus.
| Items |
Standard |
Proventus |
| Descriptio |
Album pulveris crystallini |
Obsequitur |
| Lepidium sativum |
ET'
HPLC
Reactivum |
Conformare vexillum IR
Conformare cum vexillum HPLC
Conformare |
| Solubilitas |
Gratis solutum in methanolum,acetone,ethanolum et tetrahydrofuran.Et valde solutum in acetonitrile |
Obsequitur |
| Summa immunditia |
max.0.5% |
0.18% |
| Totalis immunitas non specificata |
max. 0.2% |
0.08% |
| Singula non specificata immunditia |
max. 0.1% |
0.05% |
| Related compositis B |
max. 0.2% |
0.07% |
| Related compositis C |
max. 0.2% |
0.04% |
| Related compositis D |
max. 0.1% |
0.05% |
| Related compositis E |
max. 0.1% |
0.06% |
| Terminus cyclohexane |
max. 0.08% |
ND |
| Terminus ethylacetatis |
max. 0.1% |
0.07% |
| punctum liquescens |
81.0~84.0℃ |
82.583.2℃ |
| Aquae |
max. 0.3% |
0.21% |
| Requiesce in ignitio |
max. 0.1% |
0.07% |
| Metalla gravis |
max.0.001% |
Obsequitur |
| Assay(HPLC) |
98.0%~102.0% |
99.8% |
| Repono |
Frigidus et siccus |
| conclusio |
Obsequitur USP32 . |